$LAHO..GOLDMAN SACHS..Smart Money Is Piling Into Regenerative Medicine
Progressive Approval Could Be a Game Changer for RM Investing in Regenerative Medicine
The Goldman report discusses Samumed, a private RM company. With $300 million in funding,it’s valued at a staggering $12 billion Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.
..He will be published in the Association of American Physicians and Surgeons this winter for his research and treatment of Alzheimer’s disease with stem cell therapy.